Contract facts
Small businessNo full NAICS 541714 intel page yet. Browse NAICS intelligence
CELL AND GENE THERAPY PROCESS ANALYTICAL TECHNOLOGY AND QUALITY CONTROL TESTING is a federal Small business award for Ibc Acq Svcs Directorate (00004) held by Quantitative Biosciences, Inc. Estimated value $600K ($600K obligated). Current period of performance ends Feb 28, 2027 (potential Mar 31, 2027). Last award drew 2 bidders. Place of performance: SAN DIEGO CA.
CELL AND GENE THERAPY PROCESS ANALYTICAL TECHNOLOGY AND QUALITY CONTROL TESTING
Recompete timing
PublicCurrent PoP ends Feb 28, 2027 (154 days remaining). Agencies typically plan 12–18 months ahead — at 5.1 months out, that window is already open. The buying decision is likely already in motion.
Want the durability read on 140D0426C0012? One Pursuit Analysis, $500, inside 48 business hours.
- 48 business hours
- $500
- Credits toward the Pack
Incumbent footprint
Public recordQuantitative Biosciences, Inc — $3.4M obligated across 4 awards (firm-wide, all agencies) · lead buyer Department of Defense (DOD).
Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →
Frequently asked questions
What is contract 140D0426C0012?
140D0426C0012 (CELL and GENE therapy process analytical) is a Ibc Acq Svcs Directorate (00004) award with a potential value of $600K, currently held by Quantitative Biosciences, Inc. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.
What is 140D04-26-C-0012?
140D04-26-C-0012 is the dashed form of PIID 140D0426C0012 (CELL and GENE therapy process analytical), held by Quantitative Biosciences, Inc. Same award — SCOUT canonicalizes compact, dashed, and parent-child identifiers to one brief.
Which office awarded 140D0426C0012?
Ibc Acq Svcs Directorate (00004) awarded 140D0426C0012 to Quantitative Biosciences, Inc (potential $600K).
Who is the incumbent on 140D0426C0012?
Quantitative Biosciences, Inc is the incumbent with $3.4M across 4 related awards in SCOUT’s public footprint. The current period of performance ends Feb 28, 2027.
When does Quantitative Biosciences, Inc’s 140D0426C0012 come up for recompete?
SCOUT tracks a period-of-performance end of Feb 28, 2027. Actual solicitation timing can shift with extensions, bridges, or consolidations.
Want the durability read on 140D0426C0012? One Pursuit Analysis, $500, inside 48 business hours.
One Pursuit Analysis is $500 and credits toward the Sprint Pack. Delivery is 48 business hours. Start with the free Exposure Check if you want the list first.
No card · under a minute · then the Sprint menu
Buy one Pursuit Analysis — $500Credits toward the Sprint Pack
Compare plansData: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.